Verve Therapeutics is a technology company.
Verve Therapeutics has raised $216.0M across 3 funding rounds.
Verve Therapeutics has raised $216.0M in total across 3 funding rounds.
Verve Therapeutics has raised $216.0M in total across 3 funding rounds.
Verve Therapeutics's investors include Brainchild, F-Prime Capital Partners, GV, Oak HC/FT, Nicolas Berggruen.
Verve Therapeutics is a Boston-based biotechnology company developing single-course gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD), a leading global cause of death.[1][2][4] It targets the root genetic causes of high cholesterol, such as elevated LDL-C levels, with therapies like VERVE-101 (PCSK9 program) and others for ANGPTL3, aiming to provide permanent, one-time treatments that disrupt the chronic care model of lifelong medications.[1][3][4] Serving patients with conditions like heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease, Verve addresses the needs of hundreds of millions worldwide affected by CVD, where one person dies every 34 seconds in the U.S. alone.[4] Growth momentum includes advancing multiple programs to clinical trials, FDA Fast Track designation for its lead candidate, $860 million raised from investors, and a $497 million cash position as of early 2025 funding operations into mid-2027, with Q1 2025 collaboration revenues at $33 million despite R&D-driven net losses.[2][3]
Verve Therapeutics was founded in 2018 by pioneers in cardiology, gene editing, and drug development, led by CEO Sekar (Sek) Kathiresan, a trained cardiologist and former academic researcher whose decades of post-doctoral and lab work focused on genetic drivers of heart disease.[1][2] The idea emerged from Kathiresan's recognition of CVD as the world's top killer despite existing treatments, inspiring a shift to curative gene editing for common conditions affecting millions, unlike rare disease therapies.[2] Early traction came swiftly: the company advanced programs from nonclinical studies to first-in-human trials for PCSK9 and ANGPTL3, published proof-of-concept data showing DNA edits in the liver could clinically lower cholesterol, and secured a strong investor syndicate raising $860 million.[1][2]
Verve rides the wave of CRISPR gene editing maturation, applying it to blockbuster indications like CVD—impacting hundreds of millions—rather than niche rare diseases, potentially transforming a $100B+ chronic care market.[1][2][4] Timing aligns with accelerating biotech innovation, post-proof-of-concept data, and regulatory nods like Fast Track, amid rising demand for one-time cures as populations age and CVD persists despite statins.[1][3][4] Favorable forces include advancing base editing tech for safer, precise edits and strong partnerships fueling R&D; Verve influences the ecosystem by proving gene editing's viability for common diseases, inspiring "Verve-like" platforms and pressuring incumbents to innovate beyond lifelong pills.[2][3]
Verve's path forward centers on core ASCVD programs like Heart-2 enrollment and PCSK9/ANGPTL3 readouts, balancing investor pushes for expansion into metabolic diseases without diluting focus.[2][3][4] Trends like refined CRISPR delivery, AI-aided discovery, and payer demand for cost-saving cures will shape success, with cash supporting milestones into 2027.[3] Influence could evolve from CVD pioneer to gene editing leader for mass-market cardiometabolics if trials succeed, redefining biotech from rare to epidemic-scale impact—echoing its founding mission to end CVD's global toll through DNA-level fixes.[1][2]
Verve Therapeutics has raised $216.0M across 3 funding rounds. Most recently, it raised $94.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $94.0M Series B | Brainchild, F-Prime Capital Partners, GV, Oak HC/FT, Nicolas Berggruen | |
| Jun 1, 2020 | $63.0M Series A | Brainchild, F-Prime Capital Partners, GV, Oak HC/FT, Nicolas Berggruen | |
| May 1, 2019 | $59.0M Series A | Brainchild, F-Prime Capital Partners, GV, Oak HC/FT, Nicolas Berggruen |